Infectious Disease, Tropical Disease
Conditions
Keywords
sample, diagnostic
Brief summary
Direct constitution of collections from various samples taken on a prospective cohort of healthy volunteers, to prepare human biological samples of known characteristics (biochemical and serological in particular) and quality controlled.
Detailed description
Direct constitution of collection from various samples taken on a prospective cohort of healthy volunteers, to prepare human biological samples of known characteristics (biochemical and serological in particular) and quality controlled. This collection will allow, as a priority, a development stage, ie the establishment of the proof of concept of new diagnostic methods in the field of infectious and tropical diseases. There will be 2 cohorts (= arms) for this study: the main cohort of healthy volunteers and the N cohort, which will consist of patients with neuro-meningeal disease of infectious appearance and followed in specialized consultation.
Interventions
BIOLOGICALbiological samples
collection of blood, urine, saliva, stool, skin and mouth swabs, tears
PROCEDURElumbar puncture
collection of cerebrospinal fluid
Sponsors
Institut Pasteur
Study design
Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes
Inclusion criteria
* major subject * affiliated or benefiting from social security * having signed the information and consent form * negative HIV and HCV serology and negative HBV or vaccine serology (or old healed infection profile) * for cohort N: neuromeningeal infection during dianostic exploration
Exclusion criteria
* Volunteers with a severe or chronic pathology significantly disturbing one or more bio-clinical parameters and / or requiring the regular intake of certain drugs (anti-inflammatories or corticosteroids for example). * Woman whose pregnancy is known during the visit. * Acute infection within 15 days or taking antiviral, antibiotic, antifungal or antiparasitic drugs in the last 15 days. * Subject participating in a biomedical research or in a period of exclusion of a biomedical research. * When monitoring O +, AB +, A + and B + blood group whose erythrocyte base is kept for CEPIA research, in case of antimalarial (travel), a minimum of 5 half-lives after the last dose of antimalaria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| development of new diagnostic methods | during all the study | This collection will allow, as a priority, a first stage of development, that is to say the completion of the proof of concept of new diagnostic methods in the field of infectious and tropical diseases. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| performance improvement | during all the study | In a second step, the collection will be able to improve the essential performances (sensitivity and specificity) of the methods to the study compared to the existing methods: speed, simplicity (molecular methods, etc) and cost; and may also uncover new non-infectious biomarkers. |
Countries
France
Outcome results
None listed